乳腺癌患者右侧副乳腺在68Ga-DOTA-FAPI-04 PET/CT中显示摄取增高
68Ga-DOTA-FAPI-04 Uptake of Accessory Breast in a Patient With Breast Cancer.
PubMed 文献 · Clin Nucl Med · 2022-01-24
本文报道一例左侧乳腺癌患者在68Ga-DOTA-FAPI-04 PET/CT检查中,右侧副乳腺出现示踪剂摄取增高,最终组织病理学证实副乳腺内无恶性成分,提示非肿瘤性病变也可出现FAPI摄取增高。
要点
- 68Ga-DOTA-FAPI-04是有前景的肿瘤PET显像剂,但非肿瘤性病变也可显示FAPI摄取增高
- 左侧乳腺癌患者右侧副乳腺在68Ga-DOTA-FAPI-04 PET/CT上显示摄取增高
- 最终组织病理学证实副乳腺内无恶性成分
核心结论
- 68Ga-DOTA-FAPI-04是有前景的肿瘤显像剂,但一些非肿瘤性病变也可显示FAPI摄取增高。
研究设计与样本
- 本文为一例病例报告,患者为左侧乳腺癌,行68Ga-DOTA-FAPI-04 PET/CT检查。
主要发现
- 左侧乳腺癌患者右侧副乳腺在68Ga-DOTA-FAPI-04 PET/CT上显示示踪剂摄取增高。
- 最终组织病理学证实副乳腺内无恶性成分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68Ga-DOTA-FAPI-04 is a promising PET agent for tumor imaging. However, some nonneoplastic lesions can also show increased FAPI uptake. Herein, we presented a case of a patient with left breast cancer who showed a right accessory breast with increased tracer uptake on 68Ga-DOTA-FAPI-04 PET/CT. Final histopathology confirmed there were no malignant components in the accessory breast.
来源:Clin Nucl Med,查看原文。版权归原作者所有。
引用
- Xu T, Wang W, Yang C, et al. 68Ga-DOTA-FAPI-04 Uptake of Accessory Breast in a Patient With Breast Cancer. Clin Nucl Med. 2022. PMID: 35081060. doi:10.1097/RLU.0000000000004069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。